Related Experiment Video

Updated: Jun 25, 2025

Improving IV Insulin Administration in a Community Hospital
12:08

Improving IV Insulin Administration in a Community Hospital

Published on: June 11, 2012

18.8K

Evaluation of Sodium-Glucose Transport Protein 2 (SGLT2) Inhibitor Prescribing Patterns in Heart Failure Patients at

Emily Wo1, Cara Trulli2, Jessica Wilczynski1,3

  • 1Department of Pharmacy Practice and Administration, Ernest Mario School of Pharmacy, Rutgers University, Piscataway, NJ, USA.

Journal of Pharmacy Practice
|May 28, 2024
PubMed

Insights

Sodium-glucose cotransporter-2 inhibitors (SGLT2i) are under-prescribed for heart failure with reduced ejection fraction (HFrEF) patients at hospital discharge. Despite high eligibility, only 15.7% received SGLT2i, indicating a need for further investigation into prescribing barriers.

Area of Science:

  • Cardiology
  • Pharmacology

Background:

  • Sodium-glucose cotransporter-2 inhibitors (SGLT2i) like dapagliflozin and empagliflozin are indicated for heart failure with reduced ejection fraction (HFrEF).
  • These medications reduce the risk of cardiovascular death and heart failure hospitalizations.
  • Suboptimal prescribing may occur due to the recent availability of these indications.

Purpose of the Study:

  • To assess the prevalence of SGLT2i prescriptions at hospital discharge for HFrEF patients.
  • To identify factors influencing SGLT2i prescription rates in this population.

Main Methods:

  • Retrospective chart review of HFrEF patients discharged between April 1, 2021, and December 31, 2021.
  • Analysis of patient eligibility for SGLT2i and prescription rates at discharge.
  • Characterization of covariates associated with SGLT2i prescription.

Main Results:

  • 115 HFrEF patients were included; 94.8% were eligible for SGLT2i.
  • Only 15.7% of eligible patients received an SGLT2i prescription at discharge.
  • Patients prescribed SGLT2i had a significantly higher mean number of discharge medications (15.78) compared to those not prescribed (12.05).

Conclusions:

  • SGLT2i are significantly under-prescribed at hospital discharge for HFrEF patients, despite high eligibility.
  • Further research is needed to understand the barriers to SGLT2i prescribing in HFrEF.
  • Optimizing SGLT2i use could improve outcomes for HFrEF patients.

Keywords:
cardiologyinternal medicinepharmacy administration

More Related Videos

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion08:35

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion

Published on: May 26, 2022

3.2K
Extracellular Glucose Depletion as an Indirect Measure of Glucose Uptake in Cells and Tissues Ex Vivo10:35

Extracellular Glucose Depletion as an Indirect Measure of Glucose Uptake in Cells and Tissues Ex Vivo

Published on: April 6, 2022

2.8K

Related Concept Videos

Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
363
Secondary Active Transport01:32

Secondary Active Transport

One example of how cells use the energy contained in electrochemical gradients is demonstrated by glucose transport into cells. The ion vital to this process is sodium (Na+), which is typically present in higher concentrations extracellularly than in the cytosol. Such a concentration difference is due, in part, to the action of an enzyme "pump" embedded in the cellular membrane that actively expels Na+ from a cell. Importantly, as this pump contributes to the high concentration of...
7.0K
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
570
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
421
Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
192
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers01:22

Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers

Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
1.4K